Effects of coenzyme Q10 on vascular endothelial function in humans: A meta-analysis of randomized controlled trials

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 311-316

  Gao, Linggen ^a   Mao, Qunxia ^b   Cao, Jian ^a   Wang, Yutang ^a   Zhou, Xianliang ^c   Fan, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

^c FUWAI HOSPITAL   (China)

Author keywords

Coenzyme Q10; Endothelial function; Meta analysis

Indexed keywords

GLYCERYL TRINITRATE; UBIDECARENONE;

ATHEROSCLEROSIS; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG EFFECT; EMBASE; ENDOTHELIAL DYSFUNCTION; FLOW DEPENDENT ENDOTHELIAL MEDIATED DILATION; HUMAN; HYPERLIPIDEMIA; INFORMATION RETRIEVAL; MEDLINE; NITROGLYCERIN MEDIATED DILATATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UBIQUINONE; VASCULAR DISEASES; VASODILATION;

EID: 84858701156     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.027     Document Type: Review

References (49)

1. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
2. Tousoulis D., Antoniades C., Tentolouris C., Goumas G., Stefanadis C., Toutouzas P. l-Arginine in cardiovascular disease: dream or reality?. Vasc Med 2002, 7:203-211.
3. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
4. Landmesser U., Hornig B., Drexler H. Endothelial function: a critical determinant in atherosclerosis?. Circulation 2004, 109:II27-II33.
5. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994, 24:1468-1474.
6. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
7. Reddy K.G., Nair R.N., Sheehan H.M., Hodgson J.M. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994, 23:833-843.
8. Kitta Y., Obata J.E., Nakamura T., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009, 53:323-330.
9. Modena M.G., Bonetti L., Coppi F., Bursi F., Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002, 40:505-510.
10. Finckh B., Kontush A., Commentz J., Hubner C., Burdelski M., Kohlschutter A. High-performance liquid chromatography-coulometric electrochemical detection of ubiquinol 10, ubiquinone 10, carotenoids, and tocopherols in neonatal plasma. Methods Enzymol 1999, 299:341-348.
11. Langsjoen P.H., Vadhanavikit S., Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A 1985, 82:4240-4244.
12. Niklowitz P., Sonnenschein A., Janetzky B., Andler W., Menke T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci 2007, 3:257-262.
13. Baggio E., Gandini R., Plancher A.C., Passeri M., Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994, 15(Suppl.):s287-s294.
14. Mortensen S.A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of Q-symbio-a multinational trial. Biofactors 2003, 18:79-89.
15. Langsjoen P.H., Langsjoen A.M. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008, 32:119-128.
16. Hughes K., Lee B.L., Feng X., Lee J., Ong C.N. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese. Free Radic Biol Med 2002, 32:132-138.
17. Burke B.E., Neuenschwander R., Olson R.D. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001, 94:1112-1117.
18. Rosenfeldt F.L., Haas S.J., Krum H., et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007, 21:297-306.
19. Ho M.J., Bellusci A., Wright J.M. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2009, 2009:435. CD007.
20. Tiano L., Belardinelli R., Carnevali P., Principi F., Seddaiu G., Littarru G.P. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J 2007, 28:2249-2255.
21. Belardinelli R., Mucaj A., Lacalaprice F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006, 27:2675-2681.
22. Hamilton S.J., Chew G.T., Watts G.F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009, 32:810-812.
23. Higgins J.P., White I.R., Wood A.M. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials 2008, 5:225-239.
24. Follmann D., Elliott P., Suh I., Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45:769-773.
25. de Bree A., van Mierlo L.A., Draijer R. Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2007, 86:610-617.
26. Verhagen A.P., de Vet H.C., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
27. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
28. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
29. Raitakari O.T., McCredie R.J., Witting P., et al. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med 2000, 28:1100-1105.
30. Watts G.F., Playford D.A., Croft K.D., Ward N.C., Mori T.A., Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 2002, 45:420-426.
31. Dai Y.L., Luk T.H., Yiu K.H., et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 2011, 216:395-401.
32. Neunteufl T., Heher S., Katzenschlager R., et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000, 86:207-210.
33. Shimbo D., Grahame-Clarke C., Miyake Y., et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007, 192:197-203.
34. Moens A.L., Goovaerts I., Claeys M.J., Vrints C.J. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool?. Chest 2005, 127:2254-2263.
35. Tsai KL, Huang YH, Kao CL, et al. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. J Nutr Biochem 2011; [Epub ahead of print].
36. Kalen A., Appelkvist E.L., Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids 1989, 24:579-584.
37. Beal M.F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S189-S194.
38. Kumar A., Kaur H., Devi P., Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 2009, 124:259-268.
39. Pepe S., Marasco S.F., Haas S.J., Sheeran F.L., Krum H., Rosenfeldt F.L. Coenzyme Q10 in cardiovascular disease. Mitochondrion 2007, 7(Suppl.):S154-S167.
40. Alleva R., Tomasetti M., Battino M., Curatola G., Littarru G.P., Folkers K. The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. Proc Natl Acad Sci U S A 1995, 92:9388-9391.
41. Kaikkonen J., Nyyssonen K., Tomasi A., et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res 2000, 33:329-340.
42. Lim S.C., Lekshminarayanan R., Goh S.K., et al. The effect of coenzyme Q10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus. Atherosclerosis 2008, 196:966-969.
43. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009, 48:11-22.
44. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
45. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75.
46. Bentinger M., Tekle M., Dallner G. Coenzyme Q-biosynthesis and functions. Biochem Biophys Res Commun 2010, 396:74-79.
47. Schmelzer C., Lindner I., Vock C., Fujii K., Doring F. Functional connections and pathways of coenzyme Q10-inducible genes: an in-silico study. IUBMB Life 2007, 59:628-633.
48. Schmidt A.J., Heiser P., Hemmeter U.M., Krieg J.C., Vedder H. Effects of antidepressants on mRNA levels of antioxidant enzymes in human monocytic U-937 cells. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1567-1573.
49. Rowe G.C., Jiang A., Arany Z. PGC-1 coactivators in cardiac development and disease. Circ Res 2010, 107:825-838.